Home › Funding › Clinical Research › Draft Guidelines for Establishing and Operating a Data and Safety Monitoring Board › Appendix 2
External link, please review our disclaimer.
Draft Guidelines for Establishing and Operating a Data and Safety Monitoring Board - Appendix 2
Funding
- Funding Opportunities
- Clinical Research
- Regulations, Policies, and Guidance
- Guidelines for Developing a Data and Safety Monitoring Plan
- Draft Guidelines for Establishing and Operating a Data and Safety Monitoring Board
- NACDA Guidelines for Administration of Drugs to Human Subjects
- NACDA Guidelines for Substance Abuse Research Involving Children and Adolescents
- Bioethics
- More Clinical Trials Information
- Post-Award Concerns
- General Information
- Grant & Contract Application Process
- Funding Priorities
- Research Training
Ongoing Protocol Review
Outline of items to be reviewed
Admission Data
- Screened, admitted, reported, active
- Subject eligibility
- Demographic characteristics (total, by group)
- Recruitment and retention (total, by group)
Protocol Compliance
- Expected recruitment rate
- Study drop-outs and reason
- Data QA report
- Overall data flow
- CRFs collected, received, entered, reported by relevant CRF
- Protocol deviations
- Protocol violations
- Missing data
- Staff omission
- Subject refusal to provide data
- Monitor holding/stopping rules (e.g., lower dose)
Safety Data Report (total and by group)
- Vital signs
- Any relevant medical, psychosocial or laboratory data
- AEs (summarized in tables)
- SAEs (individual reports)
- Concomitant medications
- Concomitant illnesses
Efficacy Data Report
- Total or by group
- Masked or unblinded
- With or without statistical analysis
- Primary outcome variable
- Secondary outcome variables
This page was last updated March 16, 2004.
Search for Funding
Featured Publication
Mentoring: A Guide for Drug Abuse Researchers
Discusses the importance of quality mentorship in drug abuse research and offers suggestions for creating a successful mentor and mentee relationship.